For
over two decades now, Novartis has been at the forefront of medical
treatment of transplanted patients, and continues to remain so. From
the first introduction of cyclosporin, which allowed major advances
in transplant technology and also survival rates, Novartis has striven
to develop new products and concepts to continue to improve treatment
options. This firstly led to the improved microemulsion formulation
of cysclosporin, and then to the introduction of a monoclonal antibody
which is used at the time of transplant to help minimise risk of acute
rejection. However, Novartis are not content to stop here, and have
a huge research team, focused entirely on new developments, allowing
Novartis to boast an extremely wide and exciting transplant product
portfolio, and a product pipeline which makes Novartis the leading
company in immunosuppression.
TISSUE ENGINEERING AND TROPICAL MEDICINE:
Neoral
Simulect
Sandimmun
Myfortic
"If you have any questions
regarding your therapy, we recommend that you direct them to
your physician, pharmacist, nurse or other health care professional."
Care Guide
Nails speak volumes. Consider the perfectly sculpted fingernails of the society lady compared with lack-lustre, chipped and grubby nails. Nails speak, not only of social status, but may also reflect health or lack of it.
